- Conditions
- Rectal Cancer
- Interventions
- FOLFOX4, Cetuximab
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–17
of 17
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Colorectal Cancer
- Interventions
- Gemcitabine, avastin, 5FU/folinic acid, oxaliplatin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 15
- States / cities
- Tucson, Arizona • Beverly Hills, California • Palm Springs, California + 12 more
- Conditions
- Colorectal Cancer
- Interventions
- cetuximab, oxaliplatin, leucovorin, 5-fluorouracil
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 39
- States / cities
- Little Rock, Arkansas • Springdale, Arkansas • Fountain Valley, California + 36 more
- Conditions
- Colorectal Cancer
- Interventions
- Oxaliplatin 130 mg/m^2, Capecitabine 1000 mg/m^2, Bevacizumab 7.5 mg/kg, Placebo for bevacizumab 7.5 mg/kg, Oxaliplatin 85 mg/m^2, Leucovorin 200 mg/m^2, Fluorouracil 400 mg/m^2, Bevacizumab 5 mg/kg, Placebo for bevacizumab 5 mg/kg
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,035 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 49
- States / cities
- Berkeley, California • Fountain Valley, California • Fullerton, California + 44 more
- Conditions
- Neoplasms, Breast
- Interventions
- Lapatinib in combination with an anti-cancer agent, Lapatinib, Lapatinib in combination with an anti-cancer agent as specified by parent protocol
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 15
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Santa Monica, California + 12 more
- Conditions
- Colorectal Cancer
- Interventions
- 5 FU, Leucovorin, Oxaliplatin, capecitabine [Xeloda]
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 627 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 8
- States / cities
- Bakersfield, California • Colorado Springs, Colorado • Washington D.C., District of Columbia + 5 more
- Conditions
- Colorectal Cancer
- Interventions
- Bevacizumab, Capecitabine, 5-Fluorouracil (5-FU), Leucovorin calcium, Oxaliplatin
- Biological · Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,451 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
- Interventions
- erlotinib hydrochloride, fluorouracil, leucovorin calcium, oxaliplatin, bevacizumab
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Colorectal Cancer
- Interventions
- oblimersen sodium, fluorouracil, leucovorin calcium, oxaliplatin
- Biological · Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Rectal Cancer
- Interventions
- M1 scheme, standard long course chemoradiotherapy
- Other
- Lead sponsor
- University Medical Center Groningen
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 920 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2026
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Colorectal Cancer
- Interventions
- bevacizumab, cetuximab, FOLFIRI regimen, FOLFOX regimen, capecitabine, fluorouracil, irinotecan hydrochloride, leucovorin calcium, mitomycin C, oxaliplatin, therapeutic conventional surgery
- Biological · Drug · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Winston-Salem, North Carolina
- Conditions
- Colorectal Cancer
- Interventions
- FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 15 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 19
- States / cities
- Anchorage, Alaska • Scottsdale, Arizona • La Jolla, California + 16 more
- Conditions
- Pancreatic Adenocarcinoma, Borderline Resectable Adenocarcinoma of the Head of the Pancrease
- Interventions
- radiation therapy, surgery, mFOLFIRINOX, FOLFOX
- Radiation · Procedure · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2016
- U.S. locations
- 154
- States / cities
- Mobile, Alabama • Antioch, California • Berkeley, California + 122 more
- Conditions
- Gastrointestinal Cancer
- Interventions
- Oxaliplatin (SR96669)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Colorectal Cancer, Metastatic Cancer
- Interventions
- FOLFOX regimen, fluorouracil, isolated perfusion, leucovorin calcium, melphalan, oxaliplatin
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Locally Advanced Unresectable or Stage IV Colorectal Cancer
- Interventions
- ALIMTA plus Oxaliplatin versus Oxaliplatin plus 5-Fluorouracil and Leucovorin (FOLFOX 4 Regimen)
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- CT-011, FOLFOX
- Drug
- Lead sponsor
- Medivation, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 5
- States / cities
- Huntsville, Alabama • Tampa, Florida • New York, New York + 2 more